Compare MMT & SLGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MMT | SLGL |
|---|---|---|
| Founded | 1987 | 1997 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 251.0M | 247.1M |
| IPO Year | N/A | 2016 |
| Metric | MMT | SLGL |
|---|---|---|
| Price | $4.55 | $80.65 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $110.00 |
| AVG Volume (30 Days) | ★ 104.7K | 11.4K |
| Earning Date | 01-01-0001 | 03-19-2026 |
| Dividend Yield | ★ 8.58% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.30 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $223.84 |
| P/E Ratio | $15.00 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.31 | $0.40 |
| 52 Week High | $4.87 | $97.97 |
| Indicator | MMT | SLGL |
|---|---|---|
| Relative Strength Index (RSI) | 40.20 | 52.00 |
| Support Level | $4.53 | $32.56 |
| Resistance Level | $4.72 | $96.99 |
| Average True Range (ATR) | 0.05 | 10.79 |
| MACD | -0.00 | -1.59 |
| Stochastic Oscillator | 64.81 | 57.42 |
MFS Multimarket Income Trust is a diversified closed-end management investment company. Its investment objective is to seek high current income, but may also consider capital appreciation. The fund invests a majority of its net assets in fixed-income securities, corporate bonds of the U.S and foreign issuers, U.S Government securities, foreign government securities, mortgage-backed and other asset-backed securities of U.S and foreign issuers, and debt instruments of issuers located in emerging market countries. The portfolio of investments comprises of different sector investments such as aerospace, automotive, chemicals, electronics, and others.
Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline includes SGT-610 (Patidegib Gel 2%), a new chemical entity hedgehog signaling pathway blocker, for the chronic use and prevention of new BCC in Gorlin syndrome patients, and the topical drug candidate SGT-210 for the treatment of Darier Disease and other rare keratosis-related indications such as PC, PPK and Olmsted.